Abstract
Label-free cell phenotypic assays were performed to establish a β2-adrenoceptor (β2-AR) target model in A431 cells and a β1-AR target model in transfected HEK293-β1 cells, using known β2-AR and β1-AR agonists and antagonists. A list of natural compounds was screened on the target models, among which seven new compounds were found to be antagonistically active against β2-AR. After receptor specificity evaluations on hydroxyl carboxylic acid receptor-2 (ΗΧΑ-2), histamine receptor (H1R), and β1-adrenoceptor (β1-AR), six out of the seven compounds, including nuciferine, epiberberine, harmaline, harmine, palmatine, and columbamine, exhibited specific antagonistic activity against β2-AR. Epiberberine and palmatine showed the strongest antagonistic activities against β2-AR with IC50 values of 2.3 ± 0.2 μM and 2.6 ± 0.3 μM, respectively. Docking palmatine to the crystal structure of human β2-AR (PDB 5X7D) suggested that the ligand forms a hydrogen bond with N312 and hydrophobic interaction with several amino acid residues in the binding pocket, such as D113 and V114. The kinetic binding profile of palmatine was further investigated using co-stimulation assays. Results suggested that palmatine was a competitive antagonist for β2-AR. The...Continue Reading
References
Dec 1, 1973·Biochemical Pharmacology·Y Cheng, W H Prusoff
Jun 14, 2002·The Journal of Biological Chemistry·A Musa ZamahRobert J Lefkowitz
Mar 22, 2003·Journal of Ethnopharmacology·M FatehiZahra Fatehi-Hassanabad
Jan 3, 2006·The Journal of Allergy and Clinical Immunology·Malcolm Johnson
Mar 16, 2006·Drugs & Aging·Andrew J S Coats
Nov 30, 2006·International Journal of Toxicology·Cetin KaymakDerya Oztuna
Jan 9, 2007·Journal of Pharmacological and Toxicological Methods·Ye FangAnn M Ferrie
Feb 5, 2008·FEBS Letters·Ye Fang, Ann M Ferrie
Apr 4, 2009·Proceedings of the National Academy of Sciences of the United States of America·Peter KolbBrian K Shoichet
Aug 17, 2010·Nature Biotechnology·Ralf SchröderEvi Kostenis
Apr 13, 2011·PloS One·Yuqing LouShaojun Wen
Oct 22, 2011·Nature Protocols·Ralf SchröderEvi Kostenis
Jan 24, 2013·Journal of Pharmacological and Toxicological Methods·Ye Fang
Sep 3, 2013·Bioorganic & Medicinal Chemistry Letters·Hongtao Zhao, Amedeo Caflisch
Apr 12, 2014·Frontiers in Pharmacology·Ye Fang
Nov 26, 2014·Hypertension·Vikas KapilAmrita Ahluwalia
Dec 17, 2014·Journal of Ethnopharmacology·Jiarong LanGuoli Sun
Mar 4, 2015·Basic & Clinical Pharmacology & Toxicology·Filip Y FiskerMarkus Wehland
Feb 9, 2016·Journal of Natural Products·David J Newman, Gordon M Cragg
Mar 11, 2016·PloS One·Martilias S FarrellBryan L Roth
Jan 1, 2015·Evidence-based Complementary and Alternative Medicine : ECAM·Keshav Raj Paudel, Nisha Panth
May 8, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Ye Fang
May 25, 2016·Nature Chemistry·Tiago RodriguesGisbert Schneider
Nov 5, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·S LiebA Buschauer
Apr 1, 2017·Journal of Ethnopharmacology·Shuping LiChanghong Wang
Apr 1, 2016·Journal of Food and Drug Analysis·Hsin-Yi Hung, Tian-Shung Wu
Sep 19, 2017·Current Hypertension Reports·Steven G Chrysant, George S Chrysant
Nov 7, 2017·American Journal of Ophthalmology·Maria Antonieta GinguerraSuzana Matayoshi
Nov 15, 2017·Journal of Optometry·Patricia LomaJesus Pintor